Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy

摘要: Sunitinib represents a reasonable therapeutic option for first-line treatment of poor-risk metastatic renal cell carcinoma and the should aim at delicate balance between managing side effects to improve toxicity profile patient compliance while maintaining anticancer efficacy. Achievement complete response, although rare, is possible, even in patients. Treatment discontinuation viable alternative both tumour biology patients' quality life. To date, no molecular markers have been identified with prognostic and/or predictive value guiding decisions. Further research gaining in-depth knowledge tailored personalized therapy. We report case carcinoma, Von Hippel-Lindau loss function, which achieved maintained remission after therapy sunitinib by using reduced dosage modified schedule treatment.